Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from NLS Pharmaceutics ( (NLSP) ).
On October 30, 2025, NLS Pharmaceutics Ltd. completed its merger with Kadimastem Ltd., resulting in the formation of NewcelX Ltd., an integrated biopharmaceutical company. This merger, approved by shareholders on September 29, 2025, involved a 1-for-10 reverse stock split and the issuance of contingent value rights to existing shareholders. The newly formed company, NewcelX, aims to advance cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, with plans to initiate a Phase 2a clinical trial of AstroRx™ in ALS and further develop IsletRx™ for Type 1 diabetes treatment.
More about NLS Pharmaceutics
NewCelX Ltd. is a biotechnology company focused on developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company leverages advanced stem-cell technologies and neuroscience expertise to create scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. Headquartered in Zurich, Switzerland, NewCelX operates research and development facilities in Ness Ziona, Israel.
Average Trading Volume: 696,972
Technical Sentiment Signal: Sell
Current Market Cap: $3.15M
Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.